China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 5.34 billion. The enterprise value is 6.41 billion.
| Market Cap | 5.34B |
| Enterprise Value | 6.41B |
Important Dates
The last earnings date was Saturday, August 29, 2026.
| Earnings Date | Aug 29, 2026 |
| Ex-Dividend Date | Jun 5, 2026 |
Share Statistics
Sirio Pharma has 307.02 million shares outstanding. The number of shares has decreased by -0.22% in one year.
| Current Share Class | 307.02M |
| Shares Outstanding | 307.02M |
| Shares Change (YoY) | -0.22% |
| Shares Change (QoQ) | -3.02% |
| Owned by Insiders (%) | 20.70% |
| Owned by Institutions (%) | 14.32% |
| Float | 112.06M |
Valuation Ratios
The trailing PE ratio is 41.04 and the forward PE ratio is 15.25.
| PE Ratio | 41.04 |
| Forward PE | 15.25 |
| PS Ratio | 1.25 |
| PB Ratio | 1.75 |
| P/TBV Ratio | 2.42 |
| P/FCF Ratio | 34.30 |
| P/OCF Ratio | 8.84 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.66, with an EV/FCF ratio of 41.17.
| EV / Earnings | 49.92 |
| EV / Sales | 1.50 |
| EV / EBITDA | 13.66 |
| EV / EBIT | 25.81 |
| EV / FCF | 41.17 |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.97 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | 11.88 |
| Interest Coverage | 2.42 |
Financial Efficiency
Return on equity (ROE) is 0.93% and return on invested capital (ROIC) is 6.11%.
| Return on Equity (ROE) | 0.93% |
| Return on Assets (ROA) | 2.67% |
| Return on Invested Capital (ROIC) | 6.11% |
| Return on Capital Employed (ROCE) | 7.07% |
| Weighted Average Cost of Capital (WACC) | 5.69% |
| Revenue Per Employee | 1.54M |
| Profits Per Employee | 46,230 |
| Employee Count | 2,776 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 5.15 |
Taxes
| Income Tax | -14.94M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.17% in the last 52 weeks. The beta is 0.34, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -31.17% |
| 50-Day Moving Average | 17.05 |
| 200-Day Moving Average | 20.02 |
| Relative Strength Index (RSI) | 48.50 |
| Average Volume (20 Days) | 2,702,032 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.27 billion and earned 128.34 million in profits. Earnings per share was 0.42.
| Revenue | 4.27B |
| Gross Profit | 1.25B |
| Operating Income | 248.23M |
| Pretax Income | 11.62M |
| Net Income | 128.34M |
| EBITDA | 441.63M |
| EBIT | 248.23M |
| Earnings Per Share (EPS) | 0.42 |
Balance Sheet
The company has 782.42 million in cash and 1.85 billion in debt, with a net cash position of -1.07 billion or -3.47 per share.
| Cash & Cash Equivalents | 782.42M |
| Total Debt | 1.85B |
| Net Cash | -1.07B |
| Net Cash Per Share | -3.47 |
| Equity (Book Value) | 3.05B |
| Book Value Per Share | 10.31 |
| Working Capital | -67.61M |
Cash Flow
In the last 12 months, operating cash flow was 603.48 million and capital expenditures -447.89 million, giving a free cash flow of 155.59 million.
| Operating Cash Flow | 603.48M |
| Capital Expenditures | -447.89M |
| Depreciation & Amortization | 193.40M |
| Net Borrowing | 225.84M |
| Free Cash Flow | 155.59M |
| FCF Per Share | 0.51 |
Margins
Gross margin is 29.18%, with operating and profit margins of 5.81% and 3.00%.
| Gross Margin | 29.18% |
| Operating Margin | 5.81% |
| Pretax Margin | 0.27% |
| Profit Margin | 3.00% |
| EBITDA Margin | 10.33% |
| EBIT Margin | 5.81% |
| FCF Margin | 3.64% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 0.72%.
| Dividend Per Share | 0.13 |
| Dividend Yield | 0.72% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 60.82% |
| Buyback Yield | 0.22% |
| Shareholder Yield | 0.94% |
| Earnings Yield | 2.41% |
| FCF Yield | 2.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sirio Pharma is 23.00, which is 30.76% higher than the current price. The consensus rating is "Buy".
| Price Target | 23.00 |
| Price Target Difference | 30.76% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 10.30% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |